Related Experiment Video
Updated: Sep 1, 2025
08:10
An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy
Published on: January 25, 2019
7.9K
EFFECTS OF INTRAVITREAL BEVACIZUMAB THERAPY ON GLOMERULAR FILTRATION RATES IN PATIENTS TREATED FOR PROLIFERATIVE
David A Camp1, David A Price, Ashley E Neiweem
1Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, Indiana.
Retina (Philadelphia, Pa.)
|August 17, 2022
Summary
Repeated intravitreal bevacizumab injections for proliferative diabetic retinopathy did not lead to a long-term decline in glomerular filtration rate (GFR). This indicates that these antivascular endothelial growth factor treatments are renally safe.
Area of Science:
- Ophthalmology
- Nephrology
- Endocrinology
Background:
- Proliferative diabetic retinopathy (PDR) is a severe complication of diabetes.
- Intravitreal anti-VEGF agents, such as bevacizumab, are standard treatments for PDR.
- Potential systemic effects of intravitreal injections require investigation.
Purpose of the Study:
- To determine if repeated intravitreal bevacizumab injections for PDR are associated with a long-term decline in glomerular filtration rate (GFR).
Main Methods:
- Retrospective review of 60 patients with PDR who received at least one intravitreal bevacizumab injection.
- Analysis of baseline and end GFR (6-24 months post-injection), controlling for various clinical factors.
- Step-wise multiple linear regression used for significance testing.
Main Results:
- Patients received an average of 3.6 injections.
- No statistically significant association was found between the number of bevacizumab injections and end GFR, GFR reduction, or percent GFR reduction.
- P-values for these associations were all above 0.05.
Conclusions:
- Increased intravitreal bevacizumab injections at therapeutic doses are not linked to reduced GFR in PDR patients.
- Intravitreal anti-VEGF agents demonstrate renal safety in this patient population.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
534
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
534
01:28Angle Closure Glaucoma: Treatment
632
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
632